ArticleParasites & vectors2013
gSG6-P1 salivary biomarker discriminates micro-geographical heterogeneity of human exposure to Anopheles bites in low and seasonal malaria areas.
Article in Parasites & vectors, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Immunological surveillance using anti-gSG6-P1 IgG biomarker reveals spatio-temporal dynamics of Anopheles exposure and gaps in malaria risk assessment in the Greater Mekong Subregion.Parasite (Paris, France) · 2026Article
- Durability and effectiveness of insecticide-treated nets in Mali: a longitudinal gSG6-P1 biomarker-based assessment of children's exposure to Anopheles bites.Malaria journal · 2025Article
- Utility of plasma anti-gSG6-P1 IgG levels in determining changes in Anopheles gambiae bite rates in a rural area of Cameroon.Scientific reports · 2024Article
- Comparing malaria risk exposure in rural Cambodia population using GPS tracking and questionnaires.Malaria journal · 2024Article
- Mosquito Salivary Antigens and Their Relationship to Dengue andPathogens (Basel, Switzerland) · 2024Article
- Characterization of human exposure to Anopheles and Aedes bites using antibody-based biomarkers in rural zone of Cameroon.PloS one · 2024Article
- Characterization of Anopheles gambiae D7 salivary proteins as markers of human-mosquito bite contact.Parasites & vectors · 2022Article
- Article
- The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools.PLoS medicine · 2021Review
- Operational Evaluation of the Effectiveness of Long-lasting Insecticidal Nets on Human-Vector Contact in an African Urban Malaria Context.Open forum infectious diseases · 2021Article
- Use of anti-gSG6-P1 IgG as a serological biomarker to assess temporal exposure to Anopheles' mosquito bites in Lower Moshi.PloS one · 2021Article
- Stratifying malaria receptivity in Bangladesh using archived rapid diagnostic tests.Malaria journal · 2020Article
- IgG antibody response against Anopheles salivary gland proteins in asymptomatic Plasmodium infections in Narino, Colombia.Malaria journal · 2020Article
- Article
- Use of Anopheles salivary biomarker to assess seasonal variation of human exposure toParasite epidemiology and control · 2019Article
- Exploring the heterogeneity of human exposure to malaria vectors in an urban setting, Bouaké, Côte d'Ivoire, using an immuno-epidemiological biomarker.Malaria journal · 2019Article
- Synthetic peptides as a novel approach for detecting antibodies against sand fly saliva.PLoS neglected tropical diseases · 2019Article
- Uneven malaria transmission in geographically distinct districts of Bobo-Dioulasso, Burkina Faso.Parasites & vectors · 2018Article
- Evaluation of Malaria Urban Risk Using an Immuno-Epidemiological Biomarker of Human Exposure toThe American journal of tropical medicine and hygiene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past decade, a sharp decline of malaria burden has been observed in several countries. Consequently, the conventional entomological methods have become insufficiently sensitive and probably under-estimate micro-geographical heterogeneity of exposure and subsequent risk of malaria transmission. In this study, we investigated whether the human antibody (Ab) response to Anopheles salivary gSG6-P1 peptide, known as a biomarker of Anopheles exposure, could be a sensitive and reliable tool for discriminating human exposure to Anopheles bites in area of low and seasonal malaria transmission.
methodsA multi-disciplinary survey was performed in Northern Senegal where An. gambiae s.l. is the main malaria vector. Human IgG Ab response to gSG6-P1 salivary peptide was compared according to the season and villages in children from five villages in the middle Senegal River valley, known as a low malaria transmission area.
resultsIgG levels to gSG6-P1 varied considerably according to the villages, discriminating the heterogeneity of Anopheles exposure between villages. Significant increase of IgG levels to gSG6-P1 was observed during the peak of exposure to Anopheles bites, and decreased immediately after the end of the exposure season. In addition, differences in the season-dependent specific IgG levels between villages were observed after the implementation of Long-Lasting Insecticidal Nets by The National Malaria Control Program in this area.
conclusionThe gSG6-P1 salivary peptide seems to be a reliable tool to discriminate the micro-geographical heterogeneity of human exposure to Anopheles bites in areas of very low and seasonal malaria transmission. A biomarker such as this could also be used to monitor and evaluate the possible heterogeneous effectiveness of operational vector control programs in low-exposure areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.